Collegium Pharmaceutical is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Specialty Pharma Companies 1 ranking category Overview

ClinChoice is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Contract Research Organizations 1 ranking category Overview

Clario is a clinical trial technology and endpoint services company supporting pharmaceutical and biotechnology sponsors through electronic clinical outcome assessments, cardiac safety, medical imaging, respiratory endpoints, and trial data solutions.

Chugai Pharmaceutical is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Global Pharmaceutical Companies 1 ranking category Overview

Chiesi Global Rare Diseases is a focused rare disease platform within Chiesi Group. It develops and commercializes therapies for rare metabolic, lysosomal storage, and specialty conditions, with a growing international presence in orphan disease markets.

Chiesi Farmaceutici is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Specialty Pharma Companies 1 ranking category Overview

Cellectis is one of the earlier pioneers in gene-edited allogeneic cell therapy. The company focuses on using gene editing to create off-the-shelf CAR-T cell therapies, primarily for oncology.

Catalyst Pharmaceuticals is a specialist rare disease company focused on neuromuscular and neurological disorders. Its commercial platform is closely linked to Lambert-Eaton myasthenic syndrome and related rare neuromuscular indications.

Catalent is one of the most important global CDMO providers, with broad capabilities across biologics, sterile fill-finish, oral solid dose, softgel technologies, clinical supply services, packaging, and advanced delivery formats. The company’s platform serves pharmaceutical, biotechnology, and consumer health clients across development and commercial supply.

Caribou Biosciences is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Cell & Gene Therapy Developers 1 ranking category Overview

CanSino Biologics is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Vaccine & Immunotherapy Developers 1 ranking category Overview

Cambrex is a specialist CDMO focused on small molecule drug substance and related development services. Its capabilities include API development, process chemistry, analytical development, controlled substances, early-stage development, and commercial manufacturing.

Cabaletta Bio is a specialist developer of engineered cell therapies for autoimmune diseases. The company is part of a broader movement to apply CAR-T and related cell therapy technologies beyond cancer, especially in diseases where pathogenic immune cells may be reset or depleted.

Bristol Myers Squibb is one of the most important commercial cell therapy developers globally, with approved CAR-T therapies in hematologic malignancies and a major presence in multiple myeloma and lymphoma. Its cell therapy platform was significantly strengthened through its acquisition of Celgene, which brought key cellular therapy assets and infrastructure.

BridgeBio Pharma is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Biotechnology Firms 2 ranking categories Overview

Zevra Therapeutics is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Rare Disease & Orphan Drug Developers 1 ranking category Overview

Boehringer Ingelheim is one of the world’s largest privately held pharmaceutical companies and remains an important global player in cardiometabolic medicine, respiratory disease, immunology, oncology, and animal health. Its private ownership gives it a distinctive strategic profile compared with publicly listed pharmaceutical companies.

Blueprint Medicines is a precision medicine company with a meaningful rare disease profile through systemic mastocytosis and related kinase-driven disorders. The company focuses on targeted medicines for genomically or biologically defined diseases, including rare hematologic and mast-cell conditions.

Xenon Pharmaceuticals is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Rare Disease & Orphan Drug Developers 1 ranking category Overview

WuXi Biologics is one of the leading global biologics CRDMO providers, offering end-to-end services across biologics discovery, development, clinical manufacturing, commercial manufacturing, and regulatory support. Its integrated research-development-manufacturing model gives it a differentiated position in the biologics outsourcing market.